Unlocking the value of Asia-based companies with a focus on life sciences & sustainability, through a Nasdaq-listed SPAC.
Target Focused
Partnering with Asia-based companies with breakthrough technology in life sciences and/or sustainability.
Opportunities in Asia
Asia remains a largely underdeveloped market with high potential and untiring endeavours of innovation, but with limited access to global capital. We believe that there are enormous opportunities to bring privately held companies in Asia to the global market.
Breakthrough technology in life sciences
There is an increasing focus on the importance of healthcare innovation including the development of novel therapeutics and health technologies in many developed countries due to a growing aging population. Asian countries are experiencing significant aging populations and have begun to address the challenges of an aging society through investments in R&D, especially around healthcare and medicine.
Advancing a platform for sustainable technology
Decarbonizing the global economy and shifting to clean energy is not an easy task, but we believe that there are an increasing number of companies focused on technology aimed at accelerating the sustainable transition, as well as larger funding to fight the climate crisis in Asia.
Investment Focus
We work to unlock values by bringing privately held companies in Asia into the US capital markets.
Enormous opportunities to bring privately held companies in Asia to the U.S. capital markets
We believe listing an Asian company on a major U.S. exchange could lead to even greater performance than a listing on an Asian exchange, potentially due to access to a global investor base, brand awareness to global partners and customers, and potential opportunities for global expansion of the post-merger operations.
Most importantly, we believe that our management team and board members have the in-house capabilities and connectivity in Asia that will enable us to engage with a Target in a culturally sensitive manner, establish a trusted dialogue, cooperate throughout the de-SPAC process, and provide continued support beyond the business combination.
Unparalleled Collaboration
We have key partnerships with industry-leading firms and thought-leaders.
CrystalBioSciences
A South Korean venture capital firm founded in 2019 with 100% capital investment from CrystalGenomics, a commercial-stage biopharma company.
Leading investor in innovative startups in life sciences; selected as a General Partner of the Korea Fund of Funds(1) in April 2021.
Credian Partners
A South Korean private equity firm founded in 2014, specializing in strategic acquisitions, corporate divestitures, recapitalizations, and growth equity investments.
One of the few private equity firms in Asia to record double-digit IRR on each of its investments.
Quantum Leaps Corp.
Nobuyuki Idei
A Japanese company focused on building the bridges that bring together Japanese and Asian human resources, technologies and capital to create next-generation businesses and leaders.